The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States

References

• Thabut G, Mal H. Outcomes after lung transplantation. J Thorac Dis. 2017;9(8):650–2691.
   Web of Science ®Google Scholar
• Network O. Transplant: recipient age by recipient Gender - U.S. Transplants performed: for organ = lung., U.S.D.o.H.H. Services, Editor. 2022.
   Google Scholar
• Network O. Transplant: Recipient primary source of payment by recipient gender U.S. Transplants for organ = lung., U.S.D.o.H.H. Services, Editor. 2022.
   Google Scholar
• Young KA, Dilling DF. The future of lung transplantation. Chest. 2019;155(3):465–473.
   PubMed Web of Science ®Google Scholar
• Chambers DC, Cherikh WS, Harhay MO, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match. J Heart Lung Transplant. 2019;38(10):1042–1055.
   PubMedGoogle Scholar
• Graham CN, Watson C, Barlev A, et al. Mean lifetime survival estimates following solid organ transplantation in the US and UK. J Med Econ. 2022;25(1):230–237.
   PubMed Web of Science ®Google Scholar
• Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-A consensus report from the pulmonary council of the ISHLT. J Heart Lung Transplant. 2019;38(5):493–503.
   PubMed Web of Science ®Google Scholar
• Broaddus VC, et al. Murray & Nadel’s textbook of respiratory medicine. 7th ed. 2022. Philadelphia: Elsevier.
   Google Scholar
• Hayes D. Jr., a review of bronchiolitis obliterans syndrome and therapeutic strategies. J Cardiothorac Surg. 2011;6(1):92.
   PubMedGoogle Scholar
• Müller C, Rosmark O, Åhrman E, et al. Protein signatures of remodeled airways in transplanted lungs with bronchiolitis obliterans syndrome obtained using Laser-Capture microdissection. Am J Pathol. 2021;191(8):1398–1411.
   PubMed Web of Science ®Google Scholar
• de Jong PA, Vos R, Verleden GM, et al. Thin-section computed tomography findings before and after azithromycin treatment of neutrophilic reversible lung allograft dysfunction. Eur Radiol. 2011;21(12):2466–2474.
   PubMed Web of Science ®Google Scholar
• Verleden SE, Ruttens D, Vandermeulen E, et al. Predictors of survival in restrictive chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant. 2016;35(9):1078–1084.
   PubMed Web of Science ®Google Scholar
• Sato M, Ohmori-Matsuda K, Saito T, et al. Time-dependent changes in the risk of death in pure bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant. 2013;32(5):484–491.
   PubMed Web of Science ®Google Scholar
• Bedair B, Hachem RR. Management of chronic rejection after lung transplantation. J Thorac Dis. 2021;13(11):6645–6653.
   PubMed Web of Science ®Google Scholar
• Keller CA, Gonwa TA, White LJ, et al. Utilization and cost analysis of lung transplantation and survival after 10 years of adapting the lung allocation score. Transplantation. 2019;103(3):638–646.
   PubMed Web of Science ®Google Scholar
• Labor, U.S.B.o., Medical care in U.S. city average, all urban consumers, not seasonally adjusted; 2022.
   Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Künsebeck HW, Kugler C, Fischer S, et al. Quality of life and bronchiolitis obliterans syndrome in patients after lung transplantation. Prog Transpl. 2007;17(2):136–141.
   PubMedGoogle Scholar
• Kulkarni HS, Cherikh WS, Chambers DC, et al. Bronchiolitis obliterans syndrome-free survival after lung transplantation: an international society for heart and lung transplantation thoracic transplant registry analysis. J Heart Lung Transplant. 2019;38(1):5–16.
   PubMed Web of Science ®Google Scholar
• Chambers DC, Cherikh WS, Goldfarb SB, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-fifth adult lung and heart-lung transplant report-2018; focus theme: Multiorgan transplantation. J Heart Lung Transplant. 2018;37(10):1169–1183.
   PubMedGoogle Scholar
• Chambers DC, Yusen RD, Cherikh WS, et al. The registry of the international society for heart and lung transplantation: thirty-fourth adult lung and Heart-Lung transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36(10):1047–1059.
   PubMed Web of Science ®Google Scholar
• Verleden GM, Raghu G, Meyer KC, et al. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014;33(2):127–133.
   PubMed Web of Science ®Google Scholar
• Rana A, Gruessner A, Agopian VG, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015;150(3):252–259.
   PubMed Web of Science ®Google Scholar
• van den Berg JW, van Enckevort PJ, TenVergert EM, et al. Bronchiolitis obliterans syndrome and additional costs of lung transplantation. Chest. 2000;118(6):1648–1652.
   PubMed Web of Science ®Google Scholar
• Jones CA, Chapman DG, Weimersheimer P, et al. The burden of cost in bronchiolitis obliterans syndrome: predictions for the next decade. JHEOR. 2016;4(2):119–126., date= 2016-06-09.
   Google Scholar
• Mortimer KM, Bartels DB, Hartmann N, et al. Characterizing health outcomes in idiopathic pulmonary fibrosis using US health claims data. Respiration. 2020;99(2):108–118.
   PubMed Web of Science ®Google Scholar
• Olson AL, Maher TM, Acciai V, et al. Healthcare resources utilization and costs of patients with Non-IPF progressive fibrosing interstitial lung disease based on insurance claims in the USA. Adv Ther. 2020;37(7):3292–3298.
   PubMed Web of Science ®Google Scholar
• Rudrapatna VA, Butte AJ. Opportunities and challenges in using real-world data for health care. J Clin Invest. 2020;130(2):565–574.
   PubMed Web of Science ®Google Scholar